Purchase this article with an account.
R.J. Noecker, M. Earl; Ocular Hypotensive Efficacy of Brimonidine 0.15% as Adjunctive Therapy With Latanoprost 0.005% in Patients With Open–Angle Glaucoma or Ocular Hypertension . Invest. Ophthalmol. Vis. Sci. 2006;47(13):445.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the ocular hypotensive efficacy of brimonidine 0.15% (Alphagan P, Allergan) as adjunctive therapy with latanoprost 0.005% (Xalatan, Pfizer) in patients with open–angle glaucoma or ocular hypertension.
Multicenter, open–label, prospective evaluation of 43 patients. Enrolled patients had an IOP > 18 mm Hg after at least 6 weeks of latanoprost monotherapy. The primary outcome measure was IOP at peak drug effect (10 AM, or approximately 2 hours after the morning dose of brimonidine 0.15%). IOP at trough drug effect (8 AM, or approximately 12 hours after the evening dose of brimonidine) was also measured.
Baseline IOP was 21.9 (± 2.3) mm Hg. After 1 month, the additional mean IOP reductions from a latanoprost–treated baseline were 5.8 mm Hg (26%) at peak drug effect (P<.001) and 3.3 mm Hg (15%) at trough (P<.001). At the month 2 visit, the additional mean IOP reductions from a latanoprost–treated baseline were 5.1 mm Hg (23%) at peak drug effect (P<.001) and 2.0 mm Hg (9%) at trough (P<.001).
Brimonidine Purite 0.15% provided statistically significant additional reductions in IOP from a latanoprost–treated baseline. These findings suggest that brimonidine Purite 0.15% is an efficacious adjunctive therapy in patients using latanoprost who require additional IOP lowering.
This PDF is available to Subscribers Only